Takeda Targets Rival Over Generic Diabetes Drug
Japan-based Takeda and its Takeda Pharmaceuticals North America unit allege that Hetero's submission of an abbreviated new drug application seeking U.S. Food and Drug Administration approval for tablets containing pioglitazone, an active ingredient in Actos, infringes seven Takeda patents.
“Unless Hetero is enjoined from infringing and inducing the infringement of...
Already a subscriber? Click here to login